Table 2

(A) Summary of Treatment related AEs occurring in ≥ 5% of Patients in Either Treatment, (B) Immune-related adverse events (irAEs)

(A)
Total%Arm 1 Grade1-2%Arm 1 Grade3-4%Arm 2 Grade1-2%Arm 2 Grade3-4%
Any AEs3183.81368.4315.81161.1422.2
Fatigue924.3315.800633.300
Diarrhea616.2421.100211.100
Hypertension513.5315.80015.615.6
Joint Pain513.5210.500316.700
Nausea513.5421.10015.600
Platelet count decreased513.5210.500316.700
Pain513.50000422.215.6
Anemia410.815.300211.115.6
Chills410.8210.500211.100
Constipation410.815.300316.700
Fever38.115.300211.100
Hypoglycemia38.115.300211.100
Increased Alkaline Phosphatase38.1210.50015.600
Shortness of breath38.115.300211.100
Chest pain25.40000211.100
Dizziness25.415.30015.600
Flu like symptoms25.40000211.100
Headache25.40000211.100
Hyperglycemia25.415.30015.600
Hypermagnesemia25.415.30015.600
Hypernatremia25.415.30015.600
Hypotension25.40015.30015.6
Infusion related reaction25.415.30015.600
(B)
All%Arm 1 Grade1-2%Arm 1 Grade3-4%Arm 2 Grade1-2%Arm 2 Grade3-4%
Any513.5210.500316.700
Dermatologic38.1210.50015.600
Endocrine12.7000015.600
Hepatitis12.7000015.600
Infusion related reaction25.415.30015.600